Cells, mediators and Toll-like receptors in COPD

European Journal of Pharmacology

Volumn 585, Issue 2-3, 2008, Pages 346-353

  Sarir, Hadi ^a   Henricks, Paul A J ^a   van Houwelingen, Anneke H ^a   Nijkamp, Frans P ^a   Folkerts, Gert ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

2 adrenoceptor agonist; Chemokine; COPD; Corticosteroid; PGP; Toll like receptor

Indexed keywords

ANTIOXIDANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHEMOKINE; COLLAGEN; CORTICOSTEROID DERIVATIVE; CYTOKINE; FLUTICASONE; GLUCOCORTICOID; LONG ACTING DRUG; SALMETEROL; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DETERIORATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG POTENCY; EOSINOPHIL; FORCED EXPIRATORY VOLUME; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG FUNCTION; MACROPHAGE; MEDICAL RESEARCH; NEUTROPHIL; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANIMALS; CHEMOKINES; CYTOKINES; EPITHELIAL CELLS; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TOLL-LIKE RECEPTORS;

EID: 43049083361     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.03.009     Document Type: Review

References (160)

1. Aarbiou J., Rabe K.F., and Hiemstra P.S. Role of defensins in inflammatory lung disease. Ann. Med. 34 (2002) 96-101
2. Abel B., Thieblemont N., Quesniaux V.J., Brown N., Mpagi J., Miyake K., Bihl F., and Ryffel B. Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J. Immunol. 169 (2002) 3155-3162
3. Adcock I.M., Maneechotesuwan K., and Usmani O. Molecular interactions between glucocorticoids and long-acting β2-agonists. J. Allergy. Clin. Immunol. 110 (2002) S261-S268
4. Aderem A., and Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 406 (2000) 782-787
5. Akira S., Takeda K., and Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2 (2001) 675-680
6. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413 (2001) 732-738
7. Andersen L.W., Thiis J., Kharazmi A., and Rygg I. The role of N-acetylcystein administration on the oxidative response of neutrophils during cardiopulmonary bypass. Perfusion 10 (1995) 21-26
8. Anderson R., Feldman C., Theron A.J., Ramafi G., Cole P.J., and Wilson R. Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro. Br. J. Pharmacol. 117 (1996) 1387-1394
9. Asehnoune K., Strassheim D., Mitra S., Kim J.Y., and Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-κB. J. Immunol. 172 (2004) 2522-2529
10. Ayala A., Chung C.S., Lomas J.L., Song G.Y., Doughty L.A., Gregory S.H., Cioffi W.G., LeBlanc B.W., Reichner J., Simms H.H., and Grutkoski P.S. Shock-induced neutrophil mediated priming for acute lung injury in mice: divergent effects of TLR-4 and TLR-4/FasL deficiency. Am. J. Pathol. 161 (2002) 2283-2294
11. Balzano G., Stefanelli F., Iorio C., De Felice A., Melillo E.M., Martucci M., and Melillo G. Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function. Am. J. Respir. Crit. Care Med. 160 (1999) 1486-1492
12. Baraniuk J.N., Ali M., Brody D., Maniscalco J., Gaumond E., Fitzgerald T., Wong G., Yuta A., Mak J.C., Barnes P.J., Bascom R., and Troost T. Glucocorticoids induce β2-adrenergic receptor function in human nasal mucosa. Am. J. Respir. Crit. Care Med. 155 (1997) 704-710
13. Barnes P.J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343 (2000) 269-280
14. Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur. Respir. J. 19 (2002) 182-191
15. Barnes P.J. Mediators of chronic obstructive pulmonary disease. Pharmacol. Rev. 56 (2004) 515-548
16. Barnes P.J. Corticosteroids: the drugs to beat. Eur. J. Pharmacol. 533 (2006) 2-14
17. Barnes P.J. New molecular targets for the treatment of neutrophilic diseases. J. Allergy Clin. Immunol. 119 (2007) 1055-1062 quiz 1063-1054
18. Basu S., and Fenton M.J. Toll-like receptors: function and roles in lung disease. Am. J. Physiol. Lung Cell Mol. Physiol. 286 (2004) L887-L892
19. Bazzoni F., Cassatella M.A., Rossi F., Ceska M., Dewald B., and Baggiolini M. Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8. J. Exp. Med. 173 (1991) 771-774
20. Biswas S.K., McClure D., Jimenez L.A., Megson I.L., and Rahman I. Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. Antioxid. Redox Signal. 7 (2005) 32-41
21. Bloemen P.G.M., van den Tweel M.C., Henricks P.A.J., Engels F., Kester M.H., van de Loo P.G., Blomjous F.J., and Nijkamp F.P. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am. J. Physiol. 272 (1997) L580-L587
22. Bosken C.H., Hards J., Gatter K., and Hogg J.C. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocytochemistry. Am. Rev. Respir. Dis. 145 (1992) 911-917
23. Bridgeman M.M., Marsden M., MacNee W., Flenley D.C., and Ryle A.P. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 46 (1991) 39-42
24. Brightling C.E., Monteiro W., Ward R., Parker D., Morgan M.D., Wardlaw A.J., and Pavord I.D. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356 (2000) 1480-1485
25. Broadley K.J. β-Adrenoceptor responses of the airways: for better or worse?. Eur. J. Pharmacol. 533 (2006) 15-27
26. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., and Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Brit. Med. J. 320 (2000) 1297-1303
27. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., Yates J.C., and Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356 (2007) 775-789
28. Cantin A.M., North S.L., Hubbard R.C., and Crystal R.G. Normal alveolar epithelial lining fluid contains high levels of glutathione. J. Appl. Physiol. 63 (1987) 152-157
29. Caramori G., Romagnoli M., Casolari P., Bellettato C., Casoni G., Boschetto P., Chung K.F., Barnes P.J., Adcock I.M., Ciaccia A., Fabbri L.M., and Papi A. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax 58 (2003) 348-351
30. Cazzola M., and Dahl R. Inhaled combination therapy with long-acting β2-agonists and corticosteroids in stable COPD. Chest 126 (2004) 220-237
31. Chung M. Cytokines in chronic obstructive pulmonary disease. Eur. Respir. J. 18 (2001) 50S-59S
32. Church D.F., and Pryor W.A. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ. Health Perspect. 64 (1985) 111-126
33. Cordasco E.M., and VanOrdstrand H.S. Air pollution and COPD. Postgrad. Med. 62 (1977) 124-127
34. Cosio M.G., Majo J., and Cosio M.G. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 121 (2002) 160S-165S
35. Coultas D.B. Health effects of passive smoking bullet 8: passive smoking and risk of adult asthma and COPD: an update. Thorax 53 (1998) 381-387
36. Covert M.W., Leung T.H., Gaston J.E., and Baltimore D. Achieving stability of lipopolysaccharide-induced NF-κB activation. Science 309 (2005) 1854-1857
37. Cross C.E., van der Vliet A., O'Neill C.A., Louie S., and Halliwell B. Oxidants, antioxidants, and respiratory tract lining fluids. Environ. Health Perspect. 102 Suppl. 10 (1994) 185-191
38. Culpitt S.V., Rogers D.F., Shah P., De Matos C., Russell R.E., Donnelly L.E., and Barnes P.J. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 167 (2003) 24-31
39. Dahl R., Greefhorst L.A., Nowak D., Nonikov V., Byrne A.M., Thomson M.H., Till D., and Della Cioppa G. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164 (2001) 778-784
40. Davis R.M., and Novotny T.E. The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 140 (1989) S82-S84
41. DeForge L.E., Preston A.M., Takeuchi E., Kenney J., Boxer L.A., and Remick D.G. Regulation of interleukin 8 gene expression by oxidant stress. J. Biol. Chem. 268 (1993) 25568-25576
42. Dekhuijzen P.N. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur. Respir. J. 23 (2004) 629-636
43. Di Francia M., Barbier D., Mege J.L., and Orehek J. Tumor necrosis factor-α levels and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 150 (1994) 1453-1455
44. Di Stefano A., Capelli A., Lusuardi M., Balbo P., Vecchio C., Maestrelli P., Mapp C.E., Fabbri L.M., Donner C.F., and Saetta M. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. J. Respir. Crit. Care Med. 158 (1998) 1277-1285
45. Di Stefano A., Caramori G., Oates T., Capelli A., Lusuardi M., Gnemmi I., Ioli F., Chung K.F., Donner C.F., Barnes P.J., and Adcock I.M. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J. 20 (2002) 556-563
46. Di Stefano A., Maestrelli P., Roggeri A., Turato G., Calabro S., Potena A., Mapp C.E., Ciaccia A., Covacev L., Fabbri L.M., et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am. J. Respir. Crit. Care Med. 149 (1994) 803-810
47. Doz E., Noulin N., Boichot E., Guenon I., Fick L., Le Bert M., Lagente V., Ryffel B., Schnyder B., Quesniaux V.F., and Couillin I. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J. Immunol. 180 (2008) 1169-1178
48. Droemann D., Goldmann T., Tiedje T., Zabel P., Dalhoff K., and Schaaf B. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir. Res. 6 (2005) 68
49. Eickelberg O., Roth M., Lorx R., Bruce V., udiger J., Johnson M., and Block L.H. Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. 274 (1999) 1005-1010
50. Eriksson S. Studies in α1-antitrypsin deficiency. Acta. Med. Scand. Suppl. 432 (1965) 1-85
51. Fels A.O., and Cohn Z.A. The alveolar macrophage. J. Appl. Physiol. 60 (1986) 353-369
52. Finkelstein R., Fraser R.S., Ghezzo H., and Cosio M.G. Alveolar inflammation and its relation to emphysema in smokers. Am. J. Respir. Crit. Care Med. 152 (1995) 1666-1672
53. Fiorini G., Crespi S., Rinaldi M., Oberti E., Vigorelli R., and Palmieri G. Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. Biomed. Pharmacother. 54 (2000) 274-278
54. Gao J.J., Zuvanich E.G., Xue Q., Horn D.L., Silverstein R., and Morrison D.C. Cutting edge: bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J. Immunol. 163 (1999) 4095-4099
55. Geiser T., Dewald B., Ehrengruber M.U., Clark-Lewis I., and Baggiolini M. The interleukin-8-related chemotactic cytokines GROα, GROβ, and GROγ activate human neutrophil and basophil leukocytes. J. Biol. Chem. 268 (1993) 15419-15424
56. Hadcock J.R., Wang H.Y., and Malbon C.C. Agonist-induced destabilization of β-adrenergic receptor mRNA. Attenuation of glucocorticoid-induced up-regulation of β-adrenergic receptors. J. Biol. Chem. 264 (1989) 19928-19933
57. Halliwell B. Antioxidants in human health and disease. Annu. Rev. Nutr. 16 (1996) 33-50
58. Haynes L.M., Moore D.D., Kurt-Jones E.A., Finberg R.W., Anderson L.J., and Tripp R.A. Involvement of Toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol. 75 (2001) 10730-10737
59. Heffner J.E., and Repine J.E. Pulmonary strategies of antioxidant defense. Am. Rev. Respir. Dis. 140 (1989) 531-554
60. Hellermann G.R., Nagy S.B., Kong X., Lockey R.F., and Mohapatra S.S. Mechanism of cigarette smoke condensate-induced acute inflammatory response in human bronchial epithelial cells. Respir. Res. 3 (2002) 22
61. Henricks P.A.J., and Nijkamp F.P. Pharmacological modulation of cell adhesion molecules. Eur. J. Pharmacol. 344 (1998) 1-13
62. Henricks P.A.J., and Nijkamp F.P. Reactive oxygen species as mediators in asthma. Pulm. Pharmacol. Ther. 14 (2001) 409-420
63. Highland K.B., Strange C., and Heffner J.E. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann. Intern. Med. 138 (2003) 969-973
64. Hoebe K., Du X., Georgel P., Janssen E., Tabeta K., Kim S.O., Goode J., Lin P., Mann N., Mudd S., Crozat K., Sovath S., Han J., and Beutler B. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424 (2003) 743-748
65. Hogg J.C. Chronic obstructive pulmonary disease: an overview of pathology and pathogenesis. Novartis Found Symp vol. 234 (2001) 4-19 discussion 19-26
66. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., Cherniack R.M., Rogers R.M., Sciurba F.C., Coxson H.O., and Pare P.D. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350 (2004) 2645-2653
67. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., Takeda K., and Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162 (1999) 3749-3752
68. Ishii T., Keicho N., Teramoto S., Azuma A., Kudoh S., Fukuchi Y., Ouchi Y., and Matsuse T. Association of Gc-globulin variation with susceptibility to COPD and diffuse panbronchiolitis. Eur. Respir. J. 18 (2001) 753-757
69. Janeway Jr. C.A., and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20 (2002) 197-216
70. Johnston S.L., Papi A., Bates P.J., Mastronarde J.G., Monick M.M., and Hunninghake G.W. Low grade rhinovirus infection induces a prolonged release of IL-8 in pulmonary epithelium. J. Immunol. 160 (1998) 6172-6181
71. Jonsson S., Musher D.M., Goree A., and Lawrence E.C. Human alveolar lining material and antibacterial defenses. Am. Rev. Respir. Dis. 133 (1986) 136-140
72. Kardos P., Wencker M., Glaab T., and Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175 (2007) 144-149
73. Karimi K., Sarir H., Mortaz E., Smit J.J., Hosseini H., de Kimpe S.J., Nijkamp F.P., and Folkerts G. Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages. Respir. Res. 7 (2006) 66
74. Kawai T., Adachi O., Ogawa T., Takeda K., and Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11 (1999) 115-122
75. Kawikova I., Barnes P.J., Takahashi T., Tadjkarimi S., Yacoub M.H., and Belvisi M.G. 8-Epi-PGF2α, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro. Am. J. Respir. Crit. Care Med. 153 (1996) 590-596
76. Keatings V.M., and Barnes P.J. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am. J. Respir. Crit. Care Med. 155 (1997) 449-453
77. Keatings V.M., Collins P.D., Scott D.M., and Barnes P.J. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 153 (1996) 530-534
78. Kiri V.A., Pride N.B., Soriano J.B., and Vestbo J. Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am. J. Respir. Crit. Care Med. 172 (2005) 460-464
79. Kirkham P., and Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol. Ther. 111 (2006) 476-494
80. Kwon O.J., Au B.T., Collins P.D., Adcock I.M., Mak J.C., Robbins R.R., Chung K.F., and Barnes P.J. Tumor necrosis factor-induced interleukin-8 expression in cultured human airway epithelial cells. Am. J. Physiol. 267 (1994) L398-L405
81. Lacoste J.Y., Bousquet J., Chanez P., Van Vyve T., Simony-Lafontaine J., Lequeu N., Vic P., Enander I., Godard P., and Michel F.B. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J. Allergy. Clin. Immunol. 92 (1993) 537-548
82. Lim S., Roche N., Oliver B.G., Mattos W., Barnes P.J., and Chung K.F. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am. J. Respir. Crit. Care Med. 162 (2000) 1355-1360
83. Linden M., Hakansson L., Ohlsson K., Sjodin K., Tegner H., Tunek A., and Venge P. Glutathione in bronchoalveolar lavage fluid from smokers is related to humoral markers of inflammatory cell activity. Inflammation 13 (1989) 651-658
84. Liu H., Lazarus S.C., Caughey G.H., and Fahy J.V. Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosinophils in vitro. Am. J. Physiol. 276 (1999) L28-L34
85. Lohmann-Matthes H., Steinmuller C., and Franke-Ullmann G. Pulmonary macrophages. Eur. Respir. J. 7 (1994) 1678-1689
86. MacRedmond R.E., Greene C.M., Dorscheid D.R., McElvaney N.G., and O'Neill S.J. Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke. Respir. Res. 8 (2007) 84
87. Maestrelli P., Saetta M., Di Stefano A., Calcagni P.G., Turato G., Ruggieri M.P., Roggeri A., Mapp C.E., and Fabbri L.M. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am. J. Respir. Crit. Care Med. 152 (1995) 1926-1931
88. Majori M., Corradi M., Caminati A., Cacciani G., Bertacco S., and Pesci A. Predominant TH1 cytokine pattern in peripheral blood from subjects with chronic obstructive pulmonary disease. J. Allergy. Clin. Immunol. 103 (1999) 458-462
89. Mak J.C., Nishikawa M., and Barnes P.J. Glucocorticosteroids increase β2-adrenergic receptor transcription in human lung. Am. J. Physiol. 268 (1995) L41-L46
90. Mak J.C., Nishikawa M., Shirasaki H., Miyayasu K., and Barnes P.J. Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo. J. Clin. Invest. 96 (1995) 99-106
91. Martin T.R., and Frevert C.W. Innate immunity in the lungs. Proc. Am. Thorac. Soc. 2 (2005) 403-411
92. Medzhitov R., and Janeway Jr. C. Innate immunity. N. Engl. J. Med. 343 (2000) 338-344
93. Meyer M., Schreck R., and Baeuerle P.A. H2O2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO. J. 12 (1993) 2005-2015
94. Mio T., Romberger D.J., Thompson A.B., Robbins R.A., Heires A., and Rennard S.I. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am. J. Respir. Crit. Care Med. 155 (1997) 1770-1776
95. Montuschi P., Collins J.V., Ciabattoni G., Lazzeri N., Corradi M., Kharitonov S.A., and Barnes P.J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 162 (2000) 1175-1177
96. Morrison D., Strieter R.M., Donnelly S.C., Burdick M.D., Kunkel S.L., and MacNee W. Neutrophil chemokines in bronchoalveolar lavage fluid and leukocyte-conditioned medium from nonsmokers and smokers. Eur. Respir. J. 12 (1998) 1067-1072
97. Mortaz E., Redegeld F.A., Sarir H., Karimi K., Raats D., Nijkamp F.P., and Folkerts G. Cigarette smoke stimulates the production of chemokines in mast cells. J. Leukoc. Biol. 83 (2008) 575-580
98. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am. J. Physiol. Lung Cell Mol. Physiol. 284 (2003) L566-L577
99. Murray C.J., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 (1997) 1498-1504
100. Muzio M., Bosisio D., Polentarutti N., D'amico G., Stoppacciaro A., Mancinelli R., van't Veer C., Penton-Rol G., Ruco L.P., Allavena P., and Mantovani A. Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 164 (2000) 5998-6004
101. Nakamura H., Yoshimura K., Jaffe H.A., and Crystal R.G. Interleukin-8 gene expression in human bronchial epithelial cells. J. Biol. Chem. 266 (1991) 19611-19617
102. Nishiura H., Tanaka J., Takeya M., Tsukano M., Kambara T., and Imamura T. IL-8/NAP-1 is the major T-cell chemoattractant in synovial tissues of rheumatoid arthritis. Clin. Immunol. Immunopathol. 80 (1996) 179-184
103. O'Shaughnessy T.C., Ansari T.W., Barnes N.C., and Jeffery P.K. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am. J. Respir. Crit. Care Med. 155 (1997) 852-857
104. Okazawa A., Kawikova I., Cui Z.H., Skoogh B.E., and Lotvall J. 8-Epi-PGF2α induces airflow obstruction and airway plasma exudation in vivo. Am. J. Respir. Crit. Care Med. 155 (1997) 436-441
105. Olson T.S., and Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283 (2002) R7-R28
106. Oltmanns U., Walters M., Sukkar M., Xie S., Issa R., Mitchell J., Johnson M., and Chung K.F. Fluticasone, but not salmeterol, reduces cigarette smoke-induced production of interleukin-8 in human airway smooth muscle. Pulm. Pharmacol. Ther. 21 (2008) 292-297
107. Oostenbrink J.B., Rutten-van Molken M.P., Al M.J., Van Noord J.A., and Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur. Respir. J. 23 (2004) 241-249
108. Oshiumi H., Matsumoto M., Funami K., Akazawa T., and Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat. Immunol. 4 (2003) 161-167
109. Papi A., Romagnoli M., Baraldo S., Braccioni F., Guzzinati I., Saetta M., Ciaccia A., and Fabbri L.M. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162 (2000) 1773-1777
110. Paredi P., Kharitonov S.A., Leak D., Ward S., Cramer D., and Barnes P.J. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162 (2000) 369-373
111. Pauwels R.A., Lofdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., and Ohlsson S.V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 340 (1999) 1948-1953
112. Pesci A., Balbi B., Majori M., Cacciani G., Bertacco S., Alciato P., and Donner C.F. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 12 (1998) 380-386
113. Pilette C., Ouadrhiri Y., Godding V., Vaerman J.P., and Sibille Y. Lung mucosal immunity: immunoglobulin-A revisited. Eur. Respir. J. 18 (2001) 571-588
114. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., and Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998) 2085-2088
115. Pons A.R., Sauleda J., Noguera A., Pons J., Barcelo B., Fuster A., and Agusti A.G. Decreased macrophage release of TGF-β and TIMP-1 in chronic obstructive pulmonary disease. Eur. Respir. J. 26 (2005) 60-66
116. Pons J., Sauleda J., Regueiro V., Santos C., Lopez M., Ferrer J., Agusti A.G., and Bengoechea J.A. Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease. Respir. Res. 7 (2006) 64
117. Profita M., Giorgi R.D., Sala A., Bonanno A., Riccobono L., Mirabella F., Gjomarkaj M., Bonsignore G., Bousquet J., and Vignola A.M. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 60 (2005) 1361-1369
118. Pryor W.A., and Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann. N. Y. Acad. Sci. 686 (1993) 12-27 discussion 27-18
119. Qureshi S.T., Lariviere L., Leveque G., Clermont S., Moore K.J., Gros P., and Malo D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189 (1999) 615-625
120. Rabe K.F. Treating COPD-the TORCH trial, P values, and the Dodo. N. Engl. J. Med. 356 (2007) 851-854
121. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., Fukuchi Y., Jenkins C., Rodriguez-Roisin R., van Weel C., and Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176 (2007) 532-555
122. Rahman I., and MacNee W. Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease. Thorax 51 (1996) 348-350
123. Rahman I., van Schadewijk A.A., Crowther A.J., Hiemstra P.S., Stolk J., MacNee W., and De Boer W.I. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166 (2002) 490-495
124. Reimold A.M. TNFα as therapeutic target: new drugs, more applications. Curr. Drug Targets Inflamm. Allergy 1 (2002) 377-392
125. Repine J.E., Bast A., and Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am. J. Respir. Crit. Care Med. 156 (1997) 341-357
126. Riise G.C., Larsson S., Lofdahl C.G., and Andersson B.A. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. Eur. Respir. J. 7 (1994) 1673-1677
127. Russell R.E., Culpitt S.V., DeMatos C., Donnelly L., Smith M., Wiggins J., and Barnes P.J. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 26 (2002) 602-609
128. Russell R.E., Thorley A., Culpitt S.V., Dodd S., Donnelly L.E., Demattos C., Fitzgerald M., and Barnes P.J. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am. J. Physiol. Lung. Cell. Mol. Physiol. 283 (2002) L867-L873
129. Rutgers S.R., Postma D.S., ten Hacken N.H., Kauffman H.F., van Der Mark T.W., Koeter G.H., and Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Chest 117 (2000) 262S
130. Sabroe I., and Whyte M.K. Toll-like receptor (TLR)-based networks regulate neutrophilic inflammation in respiratory disease. Biochem. Soc. Trans. 35 (2007) 1492-1495
131. Sadeghi-Hashjin G., Folkerts G., Henricks P.A.J., Muijsers R.B.R., and Nijkamp F.P. Peroxynitrite in airway diseases. Clin. Exp. Allergy. 28 (1998) 1464-1473
132. +ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160 (1999) 711-717
133. Saetta M., Turato G., Maestrelli P., Mapp C.E., and Fabbri L.M. Cellular and structural bases of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 163 (2001) 1304-1309
134. Sarir H., Mortaz E., Karimi K., Johnson M., Nijkamp F.P., and Folkerts G. Combination of fluticasone propionate and salmeterol potentiates the suppression of cigarette smoke-induced IL-8 production by macrophages. Eur. J. Pharmacol. 571 (2007) 55-61
135. Schulz C., Kratzel K., Wolf K., Schroll S., Kohler M., and Pfeifer M. Activation of bronchial epithelial cells in smokers without airway obstruction and patients with COPD. Chest 125 (2004) 1706-1713
136. Schulz C., Wolf K., Harth M., Kratzel K., Kunz-Schughart L., and Pfeifer M. Expression and release of interleukin-8 by human bronchial epithelial cells from patients with chronic obstructive pulmonary disease, smokers, and never-smokers. Respiration 70 (2003) 254-261
137. Shapiro S.D. The macrophage in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160 (1999) S29-S32
138. Sin D.D., and Man S.F. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur. J. Pharmacol. 533 (2006) 28-35
139. Snider G.L. Chronic obstructive pulmonary disease: risk factors, pathophysiology and pathogenesis. Annu. Rev. Med. 40 (1989) 411-429
140. Strandberg K., Palmberg L., and Larsson K. Effect of formoterol and salmeterol on IL-6 and IL-8 release in airway epithelial cells. Respir. Med. 101 (2007) 1132-1139
141. Strieter R.M., and Kunkel S.L. Acute lung injury: the role of cytokines in the elicitation of neutrophils. J. Investig. Med. 42 (1994) 640-651
142. Sutherland E.R., Allmers H., Ayas N.T., Venn A.J., and Martin R.J. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 58 (2003) 937-941
143. Suzuki N., Suzuki S., and Yeh W.C. IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol. 23 (2002) 503-506
144. Takizawa H., Tanaka M., Takami K., Ohtoshi T., Ito K., Satoh M., Okada Y., Yamasawa F., Nakahara K., and Umeda A. Increased expression of transforming growth factor-β1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. 163 (2001) 1476-1483
145. Tauszig H., Jouanguy E., Hoffmann J.A., and Imler J.L. Toll-related receptors and the control of antimicrobial peptide expression in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10520-10525
146. Thoma-Uszynski S., Stenger S., Takeuchi O., Ochoa M.T., Engele M., Sieling P.A., Barnes P.F., Rollinghoff M., Bolcskei P.L., Wagner M., Akira S., Norgard M.V., Belisle J.T., Godowski P.J., Bloom B.R., and Modlin R.L. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 291 (2001) 1544-1547
147. Tomita K., Caramori G., Lim S., Ito K., Hanazawa T., Oates T., Chiselita I., Jazrawi E., Chung K.F., Barnes P.J., and Adcock I.M. Increased p21(CIP1/WAF1) and B cell lymphoma leukemia-x(L) expression and reduced apoptosis in alveolar macrophages from smokers. Am. J. Respir. Crit. Care Med. 166 (2002) 724-731
148. Traves S.L., Smith S.J., Barnes P.J., and Donnelly L.E. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J. Leukoc. Biol. 76 (2004) 441-450
149. Usmani O.S., Ito K., Maneechotesuwan K., Ito M., Johnson M., Barnes P.J., and Adcock I.M. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med. 172 (2005) 704-712
150. van der Strate B.W.A., Postma D.S., Brandsma C.-A., Melgert B.N., Luinge M.A., Geerlings M., Hylkema M.N., van den Berg A., Timens W., and Kerstjens H.A.M. Cigarette smoke-induced emphysema: a role for the B cell?. Am. J. Respir. Crit. Care Med. 173 (2006) 751-758
151. Vassalli P. The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10 (1992) 411-452
152. Vestbo J., Sorensen T., Lange P., Brix A., Torre P., and Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353 (1999) 1819-1823
153. Vincken W., van Noord J.A., Greefhorst A.P., Bantje T.A., Kesten S., Korducki L., and Cornelissen P.J. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 19 (2002) 209-216
154. Weathington N.M., van Houwelingen A.H., Noerager B.D., Jackson P.L., Kraneveld A.D., Galin F.S., Folkerts G., Nijkamp F.P., and Blalock J.E. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat. Med. 12 (2006) 317-323
155. Weber A.N., Tauszig-Delamasure S., Hoffmann J.A., Lelievre E., Gascan H., Ray K.P., Morse M.A., Imler J.L., and Gay N.J. Binding of the Drosophila cytokine Spatzle to Toll is direct and establishes signaling. Nat. Immunol. 4 (2003) 794-800
156. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., and Duff G.W. Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 3195-3199
157. Wise R., Connett J., Weinmann G., Scanlon P., Skeans M., and The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 343 (2000) 1902-1909
158. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., Takeuchi O., Sugiyama M., Okabe M., Takeda K., and Akira S. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301 (2003) 640-643
159. Zhang X., Shan P., Jiang G., Cohn L., and Lee P.J. Toll-like receptor 4 deficiency causes pulmonary emphysema. J. Clin. Invest. 116 (2006) 3050-3059
160. Zhang X., Shan P., Qureshi S., Homer R., Medzhitov R., Noble P.W., and Lee P.J. Cutting edge: TLR4 deficiency confers susceptibility to lethal oxidant lung injury. J. Immunol. 175 (2005) 4834-4838